Brain deletion of Serf2 shifts amyloid conformation in a mouse model

E. Stroo^{1#}, L. Janssen^{1#*}, O. Sin¹, W. Hogewerf¹, M. Koster², L. Harkema², S.A. Youssef^{2,3}, N. Beschorner⁴, A.H.G. Wolters⁵, B. Bakker¹, A. Thathiah^{6,7}, F. Fojjer¹, B. van de Sluis², J. van Deursen⁸, M. Jucker⁴, A. de Bruin^{2,3}, E.A.A. Nollen^{1*}

¹European Research Institute for the Biology of Ageing, University of Groningen, University Medical Centre Groningen, The Netherlands

²Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands

³Department of Pediatrics, Molecular Genetics Section, University of Groningen, University Medical Centre Groningen, The Netherlands

⁴Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

⁵Department of Biomedical Sciences of Cells and Systems, University Medical Centre Groningen, The Netherlands

⁶VIB Center for the Biology of Disease, KU Leuven Center for Human Genetics, University of Leuven, Leuven, Belgium

⁷ Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA USA

⁸Mayo Clinic, United States of America

[#]These authors contributed equally

*Corresponding authors: l.l.s.janssen@umcg.nl or e.a.a.nollen@umcg.nl

Keywords: Small EDRK-rich factor 2, SERF, protein aggregation, amyloid-beta, amyloid polymorphisms

24 **Highlights**

- 25 • Loss of SERF2 slows embryonic development and causes perinatal lethality
- 26 • SERF2 affects proliferation in a cell-autonomous fashion
- 27 • Brain-specific *Serf2* knockout does not affect viability or A β production
- 28 • Brain deletion of *Serf2* shifts the amyloid conformation of A β

29 **Abstract**

30 Loss of protein homeostasis accelerates ageing and contributes to age-related brain diseases like
 31 Parkinson's and Alzheimer's diseases. Disease-specific proteins become aggregation-prone and form
 32 amyloid deposits that characterize disease, but the biological mechanisms driving their transition in
 33 cells and tissues are poorly understood. MOAG-4/SERF accelerates aggregation and toxicity of
 34 disease-related proteins in worm- and cell models. Whether MOAG-4/SERF affects amyloid
 35 pathology in brain, however, has remained unknown. Here we show that brain-specific knockout of
 36 SERF2 is viable and shifts aggregation in a mouse model for amyloid-beta aggregation. Without
 37 affecting amyloid-beta levels, knockout of SERF2 redirects its assembly into structurally and
 38 morphologically distinct amyloid fibrils and deposits. Our results show that SERF modifies the
 39 structural outcome of the aggregation process in mammalian brain. With structural polymorphisms
 40 recently being associated with disease severity and progression, our results may help to understand the
 41 molecular basis for structural diversity and find possibilities for structure-based interventions.

Introduction

Protein aggregation is a pathological hallmark shared by several age-related neurodegenerative diseases, such as Alzheimer (AD), Parkinson and Huntington disease. The amyloid-like aggregates that accumulate in each of these diseases are composed of disease-specific proteins, i.e., amyloid-beta (A β) and tau in AD¹⁻⁴, alpha-synuclein (α -Syn) in Parkinson disease⁵ and Huntingtin (HTT) in Huntington disease⁶. While the exact molecular mechanisms underlying the disease pathology remain to be elucidated, genetic evidence indicates that these aggregation-prone proteins play a key role in the disease processes. In AD multiple causative mutations have been found in three genes: the amyloid precursor protein (*APP*)⁷⁻¹⁵, presenilin-1 (*PSEN1*)¹⁶⁻²⁰ and presenilin-2 (*PSEN2*)²⁰⁻²³ (for a full list of known AD-linked mutations see <https://www.alzforum.org/mutations>). The *APP* gene encodes the precursor protein from which A β is produced through sequential cleavage by a β - and γ -secretase. The *PSEN* genes encode the main catalytic subunit of the γ -secretase complex. The fact that all the causative mutations affect the production, length and/or structure of the A β peptides and are sufficient to cause the disease^{7,8,17-23,9-16}, is arguably the strongest piece of evidence for the involvement of A β in the disease process. Causative mutations generally affect the A β peptide in one of three ways: (i) an overall increase in A β production^{9,24}, (ii) a shift in the production of shorter variants, like A β ₄₀, to more aggregation-prone, longer variants, like A β ₄₂ (or A β ₄₃)^{11,18,25-27}, (iii) A β peptides with a modified core region, resulting in an increased propensity for aggregation^{15,28-30}. Taken together, these mutations do not necessarily increase the amount of A β , but rather increase the likelihood of A β aggregation. Similarly, several mutations in the *SNCA* gene that have been linked to Parkinson disease have been shown to alter α -Syn aggregation³¹⁻³⁶. In Huntington disease, any expansion of a polyglutamine stretch in the *HTT* gene that exceeds 36 repeats has been shown to facilitate HTT aggregation and cause the disease³⁷. Hence, changes in the folding and aggregation of these disease proteins are believed to be at the basis of the observed pathology. In addition, there is increasing evidence that distinct structural variants exist between aggregates of the same disease protein and that these polymorphs are associated with varying degrees of toxicity³⁸⁻⁴⁷. For instance, recent studies with brain samples from human AD patients have shown that variations in the disease type and disease

progression correlate with the presence of structurally different aggregates and fibrils^{40,41,48,49}. The knowledge that small changes in the structural conformation of these aggregates can have far-reaching effects on the disease manifestation could provide a new avenue for the development of therapeutics. Until now, most research into potential treatments of AD has focused on either reducing the overall amount of aggregating proteins or preventing aggregation, not modifying the aggregation process.

In a previous study, our group performed a genetic screen in *Caenorhabditis elegans* (*C. elegans*) and identified a small, intrinsically disordered protein of unknown function with the capacity to modify protein aggregation and to enhance the resulting toxicity of multiple disease-related, aggregation-prone proteins⁵⁰. This peptide was dubbed *modifier of aggregation-4* (MOAG-4) and was found to be an ortholog of two human genes: *Serf1A* and *Serf2*. Both SERF1A and SERF2 were shown to exacerbate protein aggregation and toxicity in human neuroblastoma and HEK293 cell lines as well⁵⁰. *In vitro* assays with MOAG-4 and SERF1A have demonstrated that these proteins can specifically accelerate the aggregation kinetics of amyloidogenic proteins, but do not affect aggregation of non-amyloidogenic proteins^{51,52}. For α -Syn, this amyloid-promoting effect has been shown to depend on the transient interaction of these positively-charged peptides with negatively-charged regions and the disruption intramolecular electrostatic interactions within the protein⁵¹⁻⁵³. Removal of MOAG-4 or SERF from a biological system did not change the overall levels of the aggregation-prone proteins or activate chaperone pathways known to suppress aggregation⁵⁰. Therefore, the reduced toxicity would appear to rely solely on the structural shift in the aggregation process^{50,51}. In this study, we investigate whether the removal of SERF2 modifies the aggregation of A β in the biologically more complex environment of the mammalian brain.

Results

Full-body Serf2 KO results in developmental delay and perinatal lethality in mice

To establish the role of SERF2 *in vivo*, full-body *Serf2* knockout (KO) mice were generated (Figure S1A-C). During an initial cross, using the four homozygous *Serf2* KO animal (*Serf2*^{-/-}) and eight heterozygous *Serf2* KO animals (*Serf2*^{+/-}) we obtained, only one *Serf2*^{-/-} survived the day of birth compared to 27 *Serf2*^{+/-} and 96 *Serf2* wild-type (*Serf2*^{+/+}) mice (Supplemental Table 1). After backcrossing into C57BL/6J background, interbreeding of *Serf2*^{+/-} animals did not result in any viable *Serf2*^{-/-} mice at the time of weaning (Figure 1A,1B). To determine whether *Serf2*^{-/-} mice died during fetal development, we examined the offspring at multiple developmental stages: embryonic day 13.5, 15.5 and 17.5. In all of the examined embryonic stages we observed the expected Mendelian ratio of genotypes, around 25 % *Serf2*^{+/+} and *Serf2*^{-/-} embryos and around 50 % *Serf2*^{+/-} (Chi Square: E13.5 p=0.9672; E15.5 p= 0.4432; E17.5 p=0.7674) (Figure 1B). At birth (P0), all *Serf2*^{-/-} displayed respiratory distress and the majority (5/7) died within 30 minutes of being born. At the time of weaning, the Mendelian ratio was maintained between the *Serf2*^{+/+} and *Serf2*^{+/-} animals, but no *Serf2*^{-/-} mice survived until this stage (Chi Square: P22 p<0.0001) . Examination of *Serf2* mRNA expression at E13.5 showed a 50 % reduction for *Serf2*^{+/-} and complete KO for *Serf2*^{-/-} compared to *Serf2*^{+/+} (One-way ANOVA: *Serf2*^{+/-} and *Serf2*^{-/-} vs *Serf2*^{+/+} p_{Bon}<0.0001) (Figure 1C). A similar ratio in SERF2 expression was also observed on the protein level (Figure 1D). The *Serf1* mRNA levels were not affected by the change in *Serf2* levels, indicating there is no compensatory mechanism between these genes (One-way ANOVA: p=0.2403) (Figure 1C). Further analysis of the *Serf2*^{-/-} embryonic phenotype revealed a reduction in embryo size of *Serf2*^{-/-} compared to *Serf2*^{+/+} and *Serf2*^{+/-} from E15.5 until birth (Two-way ANOVA: E17.5 WT vs KO p_{bon}<0.05; P0 WT vs ko p_{Bon}<0.0001) (Figure 1E, S1D-E). No differences in size could be observed between *Serf2*^{+/+} and *Serf2*^{+/-} embryos during the embryonic stage leading up to birth (P0). Histological examination of various tissues revealed a developmental delay of approximately one to two days in the organs of E17.5 *Serf2*^{-/-} embryos compared to the previous time points and standard embryonic development^{54,55}. This was most prominently in the lungs, through reduced expansion of alveoli and augmented tissue density, and in

the kidneys, by the increased amount of mesenchyme between the tubules and glomeruli (Figure S1F). At the time of birth, the lungs of *Serf2*^{-/-} pups displayed a significantly reduced saccular space (t-test: p= 0.0088) (Figure 1F), reflecting insufficient lung expansion and maturation. This partial fetal atelectasis seems to explain the observed respiratory distress and a likely cause of the perinatal lethality in *Serf2*^{-/-} pups. Placental abnormalities have been shown to cause impaired transfer of nutrients and oxygen to the embryo, resulting in growth delays⁵⁶. To exclude this as a potential cause, we examined the placenta at all three embryonic stages for microscopic lesions in the placental labyrinth or other changes. No genotype-related pathology could be found, indicating that absence of SERF2 in the embryo itself is responsible for the observed growth phenotype. This seems to be supported by the fact that CRISPR-induced *Serf2*^{-/-} clones of HEK293T cells display a delay in proliferation (Figure S2A). Moreover, RNA sequencing analysis of mouse embryonic fibroblasts (MEF) isolated from E13.5 embryos showed a clear enrichment of GO-terms clustered around three closely related biological functions: cell cycle, cell proliferation and cell adhesion (Supplemental Figure S2A-B). Interestingly, in the cell cycle cluster we observe an overall upregulation of factors driving cell division and downregulation of growth arrest factors in *Serf2*^{-/-} MEFs (Supplemental Table 2). This observation seems in line with a developmental delay phenotype in *Serf2*^{-/-} mice, because it is known that cell proliferation is favored over differentiation in earlier stages of embryonic development compared to later stages⁵⁷. Overall, the cell culture results point towards a cell-autonomous effect of SERF2 and suggest that loss of *Serf2* results in delayed growth. While our previous study also demonstrated a cell-autonomous function for moag-4, it did not show any effects of moag-4 deletion on the viability, life span or size of *C. elegans*⁵⁰. All together, our results suggest that *Serf2* KO causes delayed maturation of certain organs at the time of birth resulting in death. Given the cell-autonomous nature of the effects of SERF2, we aimed to avoid these adverse effects by creating an organ-specific conditional KO model.

Brain-specific KO of Serf2 does not affect viability or the Aβ production pathway

To study the effect of *Serf2* KO on amyloid pathology in the brain, we circumvented the perinatal lethality of full-body *Serf2* KO mice by generating a brain-specific *Serf2* KO mouse model (*Serf2*^{br/-}).

The conditional KO was obtained by combining our *Serf2*^{lox/lox} mice with a *Sox1-Cre* model⁵⁸ (Figure S3A). SOX1 is one of the earliest transcription factors expressed in neuronal precursors of the ectoderm from embryonic day 7.5^{59,60}. Consequently, the *Sox1* promoter was selected as a pan-neuronal driver of Recombinase cre expression to restrict homologous recombination to the central nervous system⁵⁸. Analysis of *Serf2* expression on the mRNA and protein level in various organs confirmed brain-specific ablation of *Serf2* by *Sox1*-mediated *Cre* expression in our *Serf2*^{lox/lox} mice (t-test WT vs *Serf2*^{br/-} brain: 1m p=0.0022; 3m p=0.00527) (Figure S3B-C). This conditional KO was crossed with the *APPPS1-21* amyloid (AM) model⁶¹, which contains human transgenes for both APP with the Swedish KM670/671NL mutation and PSEN1 with the L66P mutation. From this cross we obtained four experimental groups: WT, *Serf2*^{br/-}, AM and AM;*Serf2*^{br/-} (Figure 2A). Upon crossing of the *Serf2*^{br/-} with the amyloid model, we observed the expected Mendelian ratio for all the genotypes at P22, indicating that the viability is not significantly affected by brain-specific KO of *Serf2* (Chi Square: p= 0.37)(Supplemental Table 3). Based on the known progression of Aβ plaque pathology in the AM mice, we selected two age groups for further analysis: before (1 month) and after (3 months) Aβ plaque deposition (Figure 2B). Analysis of the *Serf2* mRNA levels in both age groups showed that *Serf2* expression was not altered by the plaque pathology and confirmed the KO in the *Serf2*^{br/-} and AM;*Serf2*^{br/-} mice. Some residual *Serf2* expression could be detected in the brains of the KO groups likely due to the presence of cells from non-neuronal lineage in the samples, e.g. cells from circulatory system (Two-way ANOVA: *Serf2*^{br/-} and AM;*Serf2*^{br/-} vs WT 1m p_{bon} <0.001; 3m p_{bon} <0.0001) (Figure 2C). These results were also confirmed on the protein level using western blot (Figure 2D). In accordance with the effects observed in the full-body *Serf2*^{-/-} mice, the *Serf2*^{br/-} and the AM;*Serf2*^{br/-} mice did show a reduction in brain weight compared to WT in both age groups (Two-way ANOVA: *Serf2*^{br/-} vs WT both ages p_{bon}<0.01; AM;*Serf2*^{br/-} vs WT 1m p_{bon}<0.0001; 3m p_{bon}<0.001) (Figure 2E). While the weight reduction seems to be slightly more pronounced in AM;*Serf2*^{br/-} compared to *Serf2*^{br/-}, AM by itself displayed no significant change in brain weight. This would indicate that *Serf2* ablation, *Cre* expression or a combination of both is most likely responsible for the difference in weight. However, AM mice may be more susceptible to this effect (Figure 2E). To distinguish between the effects of *Cre* expression and *Serf2* KO, we also examined the *Sox1-Cre*

mice⁵⁸ without floxed *Serf2* (*Cre*^{br}) and crossed them with *APPS1-2I*⁶¹ without floxed *Serf2*. The *Cre*^{br} mice also showed a reduction in brain weight compared to the WT controls, which was more pronounced at 1 month (One-Way ANOVA: *Cre*^{br} vs WT 1m p_{bon}<0.05) (Figure S3D), but was overall less extensive than the reduction in *Serf2*^{br/-} animals (One-way ANOVA: *Cre*^{br} vs WT p_{bon}<0.01; AM;*Cre*^{br} vs WT p_{bon}<0.001) (Figure 2F). Together, this suggests that *Cre* expression is partially responsible for the observed decrease in brain size, particularly at 1 month of age. Due to ongoing brain maturation between 1 and 3 months, all groups show a significant increase in brain weight (Two-way Anova: Age p<0.0001), but this maturation appeared unaffected by *Serf2* KO. Moreover, the difference in brain weight between WT and *Serf2*^{br/-} remained constant beyond the age of 3 months up to 11 months of age (Figure S3E). This suggests that the reduction in brain size takes place during specific stages of brain development, but that the continued development is not necessarily altered by these changes. Additional histological examination of the brains with hematoxylin-eosin staining revealed no difference in the cell density (Figure 2G), nor did we find any evidence of degeneration, apoptosis or necrosis. Apart from the overall reduction in weight, the brains showed no structural abnormalities and the tissue appeared healthy.

Next, we examined whether the brain KO of *Serf2* affected any of the key components in the A β aggregation process, like altering the levels of APP or the production of its cleavage products, A β ₄₀ and A β ₄₂. We determined the expression of human *APP* in WT, *Serf2*^{br/-}, AM and AM;*Serf2*^{br/-} mice at both 1 and 3 months of age and observed no difference due to brain specific *Serf2* KO (t-test: 1m p=0.9170; 3m p=0.9963) (Figure 2H, data from WT, *Serf2*^{br/-} not included due to lack of APP construct and absence of signal). Western blot analysis confirmed there was also no difference in APP protein levels between AM and AM;*Serf2*^{br/-} (t-test: 1m p= 0.1157; 3m p=0.5908) (Figure 2I and J). Further analysis of A β ₄₀ (Two-way ANOVA: Genotype p=0.8841; Age p<0.0001 ;Interaction p=0.8841) (Figure 2K) and A β ₄₂ (Two-way ANOVA: Genotype p=0.7006; Age p<0.0001 ;Interaction p=0.6522) (Figure 2L) showed an increase in concentration between 1 and 3 months, but this was the same in both AM and AM;*Serf2*^{br/-}. Given the variability in the A β concentrations at 3 months and the fact that the ratio between these two peptides is known to affect the aggregation process, we also

investigated the correlation between these two A β levels (Figure 2M). This analysis showed that mice with a high A β_{42} concentration display a similarly high A β_{40} level, maintaining a comparable A β_{40} /A β_{42} ratio for both AM and AM;*Serf2*^{br/-} animals. Taken together, this data suggests that SERF2 does not affect the levels of APP and its cleavage products, A β_{40} and A β_{42} . These findings are in accordance with the previously observed effects of MOAG-4 on the aggregation of polyglutamine, A β and α Syn in *C. elegans*, which modifies the aggregation process without changing the overall levels of these aggregation-prone proteins⁵⁰. While the difference in brain size is definitely a factor to be considered during further analysis, given the fact that we observed no obvious changes in the overall health, continued development and APP processing pathway of these brain-specific *Serf2* KO mice, we proceeded with our analysis of A β pathology in these animals.

Serf2 KO alters the amount of A β deposition in the brain

We next investigated whether SERF2 affects the A β aggregation by performing immunohistological analysis of the A β plaque pathology. Initially, we performed a general A β staining using the 6E10 antibody. In accordance with the known progression of A β plaque pathology in the amyloid model, we only found extracellular deposits in the 3-month-old AM and AM;*Serf2*^{br/-} mice. As expected, most plaques were found in the cortex, with some pathology beginning to spread to the hippocampus as well (Figure S4). Microscopic inspection of the A β deposits revealed a broad range of sizes with a wide variety in staining intensity and patterns, but we found no clear morphological differences between the plaque population found in AM and AM;*Serf2*^{br/-} (Figure 3A, S4). Quantification of the 6E10-positive deposits showed a slight increase in AM;*Serf2*^{br/-} compared to AM, but this just failed to reach statistical significance in the Bonferroni corrected post-hoc comparison (Two-way ANOVA: all 3m non-AM vs AM groups $p_{\text{bon}} < 0.0001$; AM vs AM;*Serf2*^{br/-} $p_{\text{bon}} = 0.063$) (Figure 3B). Given the high variability in plaque load between animals within the same experimental group, we examined whether this variability reflected the previously observed variation in A β levels. Unsurprisingly, animals with higher levels of A β_{40} (Figure 3C) and A β_{42} (Figure 3D) displayed a higher overall plaque load in both groups. More interestingly, our linear regression analysis revealed that AM;*Serf2*^{br/-} mice tend to have a significantly higher plaque load than AM mice with similar A β levels (Supplemental

Table 4). A second general A β stain with the W0-2 antibody displayed a similar slight increase in the amount of plaque deposits in AM;*Serf2*^{br/-} at 3 months (Two-way ANOVA: all 3m non-AM vs AM groups $p_{\text{bon}} < 0.0001$; AM vs AM;*Serf2*^{br/-} $p_{\text{bon}} = 0.101$) (Figure 3E). In fact, a comparison between the 6E10 and the W0-2 staining in individual animals confirmed the similarity between both staining patterns at 3 months (Figure 3F, S5, Supplemental Table S3). Interestingly, our detection algorithm also picked up a small increase in the counts of W0-2-positive foci in the 1 month AM;*Serf2*^{br/-} group (Two-way ANOVA: 1m WT vs AM;*Serf2*^{br/-} $p_{\text{bon}} = 0.088$; *Serf2*^{br/-} vs AM;*Serf2*^{br/-} $p_{\text{bon}} = 0.081$; AM vs AM;*Serf2*^{br/-} $p_{\text{bon}} = 0.127$; all other comparisons $p_{\text{bon}} > 0.999$) (Figure 3E). Closer examination of the microscopic images revealed the identified spots were not extracellular plaques, but were the result of increased levels of W0-2-positive intracellular staining in AM;*Serf2*^{br/-} (Figure S7A). Some low level intracellular W0-2 and 6E10 staining could also be observed in the other 1-month-old AM mice, but not to the extent that it was picked up by the detection algorithm (Figure S7A-B). This would suggest that the deletion of *Serf2* already alters the intracellular accumulation of A β prior to plaque deposition. Overall, these results indicate that the presence of SERF2 is indeed able to modify A β aggregation in the mouse brain.

SERF2 deficiency changes the proportion of ThS-positive cores, but not the immunoreactivity of deposits

To investigate if SERF2 also affected the amount of Thioflavin-positive fibrils, we performed Thioflavin-S (ThS) staining. Here, we again observed a large variety in the amount of ThS-positive plaques between individual animals, but we found no mean difference between AM and AM;*Serf2*^{br/-} mice (Two-way ANOVA: all 3m non-AM vs AM groups $p_{\text{bon}} < 0.001$) (Figure 3G). However, further analysis of the correlation between A β levels and the amount of ThS-positive plaques revealed that AM mice showed a positive correlation similar to the general A β stainings, while AM;*Serf2*^{br/-} mice displayed an inverse relationship (Figure 3H, 3I, Supplemental Table S3). Consequently, a general increase in A β deposits does not equate to an increase in amyloid deposition in AM;*Serf2*^{br/-} mice, as it does in AM mice (Figure 3J), further demonstrating a change in the amyloid formation in *Serf2* KO mice. In addition, we investigated microglia activation and whether we could detect a change in the

gliosis associated with A β plaques. Staining for Iba1 showed a slight increase in the AM;*Serf2*^{br/-} mice compared to AM (Two-way ANOVA: 3m non-AM groups vs AM $p_{\text{bon}} < 0.01$; non-AM groups vs AM;*Serf2*^{br/-} $p_{\text{bon}} < 0.0001$; AM vs AM;*Serf2*^{br/-} $p_{\text{bon}} < 0.01$) (Figure 3K), similar to what was observed with the 6E10 staining (Figure 3B). We therefore examined if this increase was simply related to the increase in A β deposits or if AM;*Serf2*^{br/-} also displayed a different immune response to plaques compared to AM. Our analysis revealed a similar correlation between 6E10-positive deposits and immune response for AM and AM;*Serf2*^{br/-} mice, suggesting the deposits evoked a similar immune response in both groups (Figure S6A, Supplemental Table S3).

Knockout of Serf2 changes the plaque composition and fibril structure

Given the differences in the reactivity of the A β deposits between the various stains, we decided to explore the composition within the individual plaques in greater detail. To this end, we made use of two luminescent conjugated oligothiophenes (LCO), qFTAA (quadro-formylthiophene acetic acid) and hFTAA (hepta-formylthiophene acetic acid). These LCOs are small hydrophobic ligands with a high affinity for binding distinct types of amyloids and can easily be distinguished from each other based on their spectral properties⁶². The smallest of the two molecules, qFTAA, is characterized by a peak in its emission spectrum around 500 nm and has been shown to stain compact, multifilament fibril structures, coinciding with ThT and Congo red staining⁶²⁻⁶⁴. Whereas hFTAA emits in the yellow to red range with a peak around 600 nm and is capable of staining prefibrillar (non-thioflavinophilic) and single fibril aggregates found during the lag-phase of in vitro ThT kinetics (Figure 4A). The prefibrillar aggregates were shown to be stained with 6E10, but not Congo red, ThT or qFTAA⁶²⁻⁶⁴. Previous studies have shown that by combining LCO dyes it is possible to uncover structural differences in plaque composition^{49,64,65}. We performed confocal spectral imaging of randomly selected plaques in 3-month-old AM and AM;*Serf2*^{br/-} mice after double staining with both LCOs and determined the ratio of the light intensity emitted at 502nm and 588nm as a measure for the relative amounts of fibrillar and prefibrillar aggregates within the individual plaques. An exploratory frequency analysis of the intensity ratios found in both groups revealed a three-peak pattern in which the middle peak was similarly represented in both groups (Figure 4B, green area). The first peak,

however, was predominantly found in AM mice (Figure 4B, red area), while the third peak was mainly detected in AM;*Serf2*^{br/-} (Figure 4B, blue area). This shift in ratio was also reflected by a significant difference in the average intensity ratio between AM and AM;*Serf2*^{br/-} (t-test p<0.001) (Figure 4C). This increase in intensity ratio could not be observed in AM;*Cre*^{br} mice (t-test p=0.6047) (Figure 4C, insert), indicating that this effect is caused by the *Serf2* KO and unrelated to *Cre* expression. Given the fact that AM;*Cre*^{br} animals also show a decrease in brain weight without a change in LCO staining, this would also suggest that the weight reduction is not a factor in these results. Although, as the change in brain weight is more pronounced in *Serf2*^{br/-} animals, we cannot completely exclude this as a potential contributing factor. Next, we examined if the change in the intensity ratio correlated with the slight increase in 6E10-positive deposits we observed in AM;*Serf2*^{br/-} (Figure 4D). However, the higher average intensity ratio in AM;*Serf2*^{br/-} mice was not related to this general plaque load nor the number of W0-2- or ThS-positive deposits (Figure S6B, S6C). Further microscopic analysis of low intensity ratio deposits from AM mice showed a plaque with a qFTAA- and hFTAA-positive core and a border that was only stained by hFTAA (Figure 4E, left panels). The high intensity ratio deposits from AM;*Serf2*^{br/-} mice, on the other hand, revealed a qFTAA-positive core, but virtually no hFTAA-staining (Figure 4E, right panels), demonstrating the difference in plaque composition reflected by the shift in LCO intensity ratios. Additionally, we visualized the global fibrillar structure of the plaques on a nanometer scale using high resolution, scanning transmission electron microscopy (STEM). Overall, STEM images of plaques from AM;*Serf2*^{br/-} tended to show more condensed plaques composed of short, thick and densely packed bundles of fibers with little space in between (Figure 4F, right panels). In the AM mice, however, the plaques we observed displayed more loosely packed fibrils (Figure 4F, left panels). Taken together, these findings suggest *Serf2* KO in mice leads to a shift in the Aβ aggregation process, resulting in an altered structural composition of the plaques.

Discussion

Previous studies identified MOAG-4 and its human orthologs SERF1A and SERF2 and their potential to modify the aggregation of amyloidogenic proteins. While the exact endogenous biological function of these peptides remains unclear, a recent study has provided evidence for RNA-binding properties of

SERF1A through a region which is highly conserved in MOAG-4 and SERF2⁶⁶. In this study, we have demonstrated in cells and mice that SERF2 provides a growth advantage during development. The absence of SERF2 or MOAG-4 in itself does not appear to be lethal in cells, worms or the brain-specific KO mice. Therefore, we postulate that the observed perinatal lethality in the full-body KO mice is a secondary effect of the delay in growth due to insufficient maturation of certain organs at birth. This appears to be supported by the fact that some pups survived the initial minutes after birth and incomplete penetrance of the lethality in the earliest generations with mixed genetic background. The 129SV genetic background present in these mice is known to have a gestation period that is on average around one day longer than C57/BL6J mice⁶⁷, which could result in improved lung maturation. While the exact function of SERF2 remains unknown, we propose its effects on growth and development are most likely caused through one of two mechanisms: either SERF2 facilitates cell proliferation or it protects cells from stressors that create an unfavorable environment for cell division. In the latter case, we would expect to see an upregulation of stress pathways or cell cycle arrest proteins inhibiting the cell cycle in *Serf2*^{-/-} cells. Interestingly, the RNA seq analysis of the MEFs from our *Serf2*^{-/-} mice showed the exact opposite. Cell cycle driving factors were upregulated (e.g. cyclins). Whereas, stress signaling and cell cycle inhibiting factors were downregulated (e.g. GADD45 and GAS1). Thus, the *Serf2*^{-/-} cells actually displayed an increased stimulation of cell proliferation mechanisms, which would fit with cells from earlier stages of embryonic development. This would suggest the first mechanism, with a beneficial role for SERF2 in the efficient execution of cell proliferation, as the most likely explanation for the observed growth effect. Furthermore, an increase in cellular stress would most likely result in decreased health and fitness. However, *moag-4* deletion worms showed no changes in life span compared to controls⁵⁰ and, apart from the initial growth deficit, the tissues of *Serf2* KO mice appeared healthy and continued to develop similarly to controls after birth. A recent study showed SERF1a might play a role as an RNA-organizing protein, which localizes to membraneless nuclear organelles, like the nucleolus, under normal physiological conditions. However, under stress conditions, it was shown to migrate to the cytoplasm, where it could drive amyloid toxicity.⁶⁶ While there was no compensatory upregulation of SERF1 in response to SERF2 KO and a similar mode of action remains to be demonstrated for SERF2, the structural

homology of the two proteins would suggest a comparable function. Given the importance of nucleolar disassembly and reassembly in cell cycle control^{68,69}, an RNA-organizing function could explain how SERF2 facilitates cell proliferation. This developmental role would have limited biological importance in non-proliferating, differentiated cells, like the brain's neurons or the cells of adult *C. elegans*, and might also explain why we saw no adverse effects in the *moag-4* deletion worms or our adult *Serf2*^{br/-} mice. While a reduced biological importance of SERF2 later in life could prove interesting with regard to the treatment of age-related neurodegenerative disorders, further exploration of SERF2's endogenous function and how it evolves with ageing will be needed to fully assess this mechanism's therapeutic potential.

In this study, we confirmed the ability of SERF2 to modify the A β pathology *in vivo* in a mouse model without changing the overall A β levels. We showed that mice lacking SERF2 were more prone to form A β deposits and that the composition of these deposits was structurally different. In AM mice higher levels of A β result in an increase in the numbers of A β deposits as well as an increase in the number of ThS-positive deposits. AM;*Serf2*^{br/-} mice, on the other hand, also show an increase in A β deposits, but this did not lead to higher numbers of ThS-positive plaques, indicating an altered dynamic for amyloid formation. These findings were further corroborated by the LCO spectra, which revealed that the plaques in AM;*Serf2*^{br/-} mice have a different conformation of pre-fibrillar and fibrillar A β compared to AM mice. Finally, STEM imaging also confirmed a globally altered structure of the amyloid fibrils in the plaques. Amyloid fibrils are formed through a nucleated self-assembly process characterized by a structural conformation to a β -strand secondary structure and the formation of a critical nucleus during the initial oligomerization. The nuclei act as seeds from which the fibrils grow and have been shown to propagate a specific fibril structure^{41,70}. *In vitro* kinetic assays with SERF and MOAG-4 have shown that these peptides accelerate aggregation by acting on the nucleation phase^{51-53,71}. Recently, we have shown that SERF2 is equally capable to drive amyloid formation of α -Syn and A β *in vitro* through a conserved, positively charged region⁷². Meanwhile, another study has demonstrated that binding of the intrinsically disordered protein yeast SERF to α -Syn and A β results in fuzzy complexes with heterogeneous structural conformations that are more extended in

nature⁷¹. For α -Syn, the disruption of intra-molecular electrostatic interactions by the positively charged region of MOAG-4/SERF1 was found to expose an amyloid nucleation site^{52,53}. Intra-molecular electrostatic interactions have also been proven to play a part in the dynamics and structure of the A β monomer folding, which is at the basis of nucleus formation. In fact, several of the familial AD mutations located within the A β sequence and reported not to affect the A β levels, appear to exert their effects by modifying the intra-molecular interactions and monomer folding^{30,73–75}. These single amino acid modifications in the A β sequences also result in alterations in the aggregation kinetics, fibril structure and aggregate toxicity in *in vitro* studies^{29,76,77}. Moreover, patients and mouse models with these mutations show differences in the localization of A β accumulation and deposition, as well as differences in its structure, giving rise to specific disease phenotypes. For instance, while some mutations result in increased A β deposition and altered plaque structure, other mutations at the same location result in cerebral amyloid angiopathy with A β deposition in blood vessels rather than the brain parenchyma or even an absence of extracellular A β deposition^{15,28,82,83,30,65,73,77–81}. In addition, some of these mutants showed increased intracellular A β accumulation which differed in structure-specific staining characteristics^{83–85}. The differences in A β pathology between these mutants seem to display some similarities to the changes we observed between our AM and AM;*Serf2*^{br/-} mice. Together with the *in vitro* findings about the mechanism of SERF2 interaction with aggregation-prone proteins, this would appear to suggest modulation of intra-molecular interactions and altered nucleation as the mechanism for SERF2's effect on aggregation and amyloid formation in our mice. Interestingly, there is increasing evidence that qualitative, structural properties may be more related to toxicity than the quantity of aggregates and deposits. Recent studies have provided increasing evidence that structural polymorphs are associated with differences in toxicity and different clinical phenotypes in sporadic and familial cases^{40,41,47–49}. One recent study demonstrated that these structural conformations of distinct disease phenotypes could also be detected by differences in the LCO spectra of the plaques and that these spectral properties could, at least partially, be transmitted to a mouse model through seeding⁴⁹. While the effect of familial mutations on the formation of distinct polymorphs has already been explored by others^{49,84–86}, our study provides the first evidence of a single endogenous factor, separate from A β and its production pathway, contributing to a structural

shift of amyloid pathology in a mammalian system. Further research will be needed to elucidate the exact structural changes at an atomic level and if they affect toxicity and disease progression similarly to what was previously observed in *C. elegans*. This will provide new insights into the structural properties and diversity of disease-protein aggregation, contributing to a better understanding of the variability in disease manifestation and open up previously unexplored avenues for therapeutic research.

Materials and methods

Animals

Serf2 knockout mice were generated by introducing *loxP* sites in the *Serf2* gene on either side of exon 2, in accordance with the ‘knockout-first’ allele design as described by Skarnes and colleagues⁸⁷. Full-body *Serf2* knockout mice were obtained by crossing these floxed mice with 129SV mice expressing *Cre* under the *Hprt* promoter, resulting in the removal of exon 2 by *Cre*-mediated recombination (Figure S1A). Subsequently, these mice with mixed background were backcrossed at least 6 times to a C57Bl/6J background. Homozygous and heterozygous full-body *Serf2* knockout mice were examined with their wild-type littermates at embryonic day 13.5, 15.5 and 17.5, as well as at the day of birth (P0) and day of weaning (P22).

Heterozygous *Sox1-Cre* mice⁵⁸ were backcrossed at least 8 times to a C57BL/6J background. These animals were also used as controls to differentiate between effects of *Cre* expression and *Serf2* knockout. To generate the conditional *Serf2* knockout mice, the floxed mice were first crossed with Tg(ACTFLPe)9205Dym (Jackson#003800) mice to flip the FRT site and remove the lacZ and neo cassette. Subsequently, these mice were backcrossed at least 6 times to a C57BL/6J background. Finally, the resulting homozygous *Serf2*^{flox/flox} mice were crossed with the backcrossed *Sox1-Cre* mice, to obtain the brain-specific *Serf2* knockout mice (Figure S3A). The conditional *Serf2* knockout mice were crossed with the APPPS1-21 transgenic mice (APP (KM670/671NL)/PS1(L166P), Rottenburg, Germany)⁶¹. A final cross between heterozygous APPPS1-21; *Serf2*^{flox/flox} and heterozygous *Sox1-Cre*; *Serf2*^{flox/flox} resulted in four experimental groups of *Serf2*^{flox/flox} mice: *Sox1-Cre*^{-/-}; APPPS1-21^{-/-} (WT),

Sox1-Cre^{+/-}; APPPS1-21^{-/-} (*Serf2^{br/-}*), *Sox1-Cre^{-/-}*; APPPS1-21^{+/-} (AM) and *Sox1-Cre^{+/-}*; APPPS1-21^{+/-} (AM;*Serf2^{br/-}*) (Figure 2A). All experimental groups were tested at 1 month or 3 months of age.

All experiments were approved by the Institutional Animal Care and Use Committee of the University of Groningen (Groningen, The Netherlands). All mice were maintained on a C57BL/6J background and housed in a 12:12 hour light/dark cycle and the animals had ad libitum access to food and water. Genotyping of embryos was performed using tail and yolk sac biopsies. Otherwise, ear biopsies were used. DNA was purified using prepGEM® Tissue kit according to a protocol adapted from the manufacturer (ZYGEPTI0500, ZyGEM, VWR International BV) and subjected to PCR using the primers listed in Supplemental Table S5. Mice were terminated through CO₂-inhalation and cervical dislocation for subsequent tissue collection.

Embryo processing and histochemistry

Embryos were fixed in 4 % formalin (Kinipath) for a minimum of 24 hours at room temperature. For the pathological analysis, the embryos and their placenta were bisected longitudinally and embedded in paraffin. Using the microm HM 340E (Thermo Scientific) 4 µm sections were cut for the hematoxylin-eosin (HE) staining. The HE sections were incubated at 60 °C for 15 minutes. Next, sections were deparaffinized and rehydrated in xylene (2x), 100 % alcohol (2x), 96 % alcohol, 70 % alcohol and water. HE staining was performed by incubation with hematoxylin for 4 minutes, water for 10 minutes, eosin for 1 minute and water for 10 seconds. After staining all sections were dehydrated in 70 % alcohol, 96 % alcohol, 100 % alcohol (2x) and xylene (2x).

Brain processing

Upon termination, all brains were collected and weighed. From each experimental group three whole brains were collected for HE staining according to the protocol described under embryo processing. HE-stained sections were scanned with the TissueFAXs microscope using 20X objective. Images were processed for nuclei counts using Histoquest software. The remaining brains were divided sagittally. The left hemibrain was prepared for histochemistry and fixed in 4 % paraformaldehyde (PFA) for 48

hours at room temperature on a shaker. Next, the brains were placed in 30 % sucrose for approximately 12 hours. Afterwards, the excess sucrose was removed and hemibrains were frozen in molds with Tissue Tek O.C.T. compound (Sakura, The Netherlands) on dry ice. The right hemibrain was snap frozen in liquid nitrogen and stored at -80°C. This tissue was homogenized using a liquid nitrogen cooled mortar for subsequent protein and RNA analysis.

Quantitative RT-PCR

Total RNA was extracted from snap frozen tissue using TRIzol Reagent (Life Technologies) according to the manufacturers' description. Total RNA quality and concentration were assessed using a NanoDrop 2000 spectrophotometer (Thermo Scientific/Isogen Life Science). cDNA was made from 1,5 µg total RNA with a RevertAid H Minus First Strand cDNA Synthesis kit (Thermo Scientific) using random hexamer primers. Quantitative real-time PCR was performed using a Roche LightCycler 480 Instrument II (Roche Diagnostics) with SYBR green dye (Bio-Rad Laboratories) to detect DNA amplification. Relative transcript levels were quantitated using a standard curve of pooled cDNA solutions. Expression levels were normalized to β -Actin or 18S mRNA levels. The primers for Quantitative PCR used are listed in Supplemental Table S5.

Western Blot analysis

For SERF2 analysis tissues were homogenized in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 5mM EDTA, 0.5 % SDS, 0.5 % SDO, 1 % NP-40) with protease inhibitor cocktail (Roche) and incubated on ice for 1 hour, spun down at 13,300 rpm for 30 minutes at 4 °C and the supernatant was collected. Protein measurements were performed using a BCA kit (Pierce) and 150 µg was loaded on a 10-20 % tris/tricine SDS-page gels (Bio-Rad Laboratories) and blotted onto 0,2 µm nitrocellulose membrane (Bio-Rad Laboratories). Membranes were incubated overnight with SERF2 (1/1500, Protein tech) or Actin (1/10 000, MP biomedical) antibody. Next, the membranes were incubated with anti-mouse or –rabbit secondary antibodies tagged with horseradish peroxidase (1/10 000, Bio-Rad Laboratories) for one hour at room temperature and visualized by chemiluminescence (Amersham ECL prime western blotting detection reagent, VWR).

RNA sequencing

RNA sequencing analysis was performed on three MEF cell lines from *Serf2*^{-/-} mice and four *Serf2*^{+/+} littermate controls. Total RNA was isolated from MEFs using the Qiagen RNeasy isolation kit. Integrity of the RNA based on RIN scores as determined by a Bioanalyzer (Agilent). RNA-sequencing libraries were prepared using TruSeq Stranded Total RNA with Ribo-Zero Human/Mouse/Rat (RS-122-2201; Illumina, CA, USA) according to manufacturers' protocol. Pooled libraries were sequenced on an Illumina HiSeq 2500 (single-end 50 bp). Reads were aligned to the mouse reference genome (mm10) using a splicing-aware aligner (StarAligner). Aligned reads were normalized to fragments per million (FPM), excluding low abundance genes (mean FPM > 1 in at least two samples). The raw count data were pre-processed using the programming language R (3.4.0) [R Core Team, 2016, available online at: www.r-project.org], the program RStudio (1.0.143) [RStudio Team, 2016, available online at: <http://www.rstudio.com/>] and the EdgeR package (3.18.0) (Robinson et al., 2010). Genes that displayed FPM value > 1 in at least two libraries were retained, resulting in a list of 12,808 genes for differential analysis. Differentially expressed (DE) genes between the *Serf2*^{+/+} and *Serf2*^{-/-} MEFs were identified using the EdgeR general linear model approach. After statistical correction for multiple comparisons with the "false discovery rate" (FDR) method (FDR < 0.05), a list of 738 DE genes was obtained. DAVID (6.8) was used to perform functional annotation analyses on this gene list and to identify significantly enriched gene ontology (GO) terms [using GOTERM_BP_DIRECT]^{88,89}. The connectivity between the enriched GO terms was further examined by determining the amount of associated genes found (AGF) that were shared between two GO terms. The most significant relationships (where a GO term shared > 25 % of the AGF) were mapped in a network using the igraph package (1.0.1). The color of the edges reflects the major node, with the largest amount of AGF, in each relationship. The weight of the edges was determined by the percentage of AGF shared by the minor node in the relationship. We defined three clusters of GO-terms, where multiple minor GO-terms connected to one or two central, major GO-terms. Minor GO-terms were always clustered with the major GO-term with whom they shared the strongest connection. One GO term, positive

regulation of the apoptotic process, showed no direct relation with one of the major GO-terms and was therefore assigned to the only cluster it had a significant connection with (Figure S2A-B).

ELISA

The ELISA experiments were performed as described previously⁹⁰. Briefly, the frozen brain samples were homogenized in tissue protein extraction reagent (Pierce) supplemented with complete protease inhibitors (Roche), and centrifuged for 1 hour at 430 000 g at 4 °C. The supernatant was used for ELISA. The A β ₄₀ and A β ₄₂ levels were determined by standard sandwich ELISAs using end-specific antibodies (Janssen Pharmaceutical), and the monoclonal JRFcA β ₄₀/28 and JRFcA β ₄₂/26 antibodies as the capture antibodies. Horseradish peroxidase conjugated JRFA β N/25 or JRFA β N/25 were used as the detection antibodies for, respectively, human A β or murine A β . Samples were loaded in triplicate for each ELISA. The ELISAs were performed in triplicate for the 3-month-old animals and in duplicate for the 1-month-old animals.

Brain immunohistochemistry

To evaluate A β -related pathology, the brain was cut in 30 μ m thick serial cryostat sections. A series of sections was selected with 300 μ m spacing between individual sections and blind-coded, 6 per mouse for the 6E10 and Iba1 antibody and 3 per mouse for W02. Sections were fixed in 4 % PFA for 10 minutes, followed by 20 minutes antigen retrieval in citrate acid (pH 6.0) and 30 minutes in 1 % H₂O₂ in methanol. Next the sections were incubated for 1 hour in 10 % goat or donkey serum, depending on the secondary antibody, and immunolabeled overnight with antibodies against A β , and Iba1 (Supplemental Table S6). The sections were washed and incubated with the complementary biotinylated secondary antibody (1/500, Jackson ImmunoResearch) for 2 hours. Next, sections were incubated in ABC complex and reacted with diamino-benzidine (0.5 mg/ml H₂O with 0.01 % H₂O₂). The stained sections were scanned with the TissueFAXs microscope using 20X objective. All images were analyzed using the Fiji platform of the ImageJ software⁹¹. For unbiased feature detection we used a single automated script with optimized threshold method and parameters for the complete image set of each staining method.

Thioflavin-S Staining

A 300 μm -spaced series of three blind-coded 30 μm sections were fixed in 4 % PFA for 10 min, followed by incubation in 0.25 % potassium permanganate solution for 15 min, and a bleaching step with 1 % potassium metabisulfite/1 % oxalic acid for 5 min, incubation with 0.02 % Thioflavin-S solution in 50 % ethanol (Sigma T1892) for 8 minutes, rinsed with water between every step. Finally the sections were incubated with 1 $\mu\text{l/ml}$ DAPI. The sections were analyzed as described for the immunostained sections. Stained sections were scanned with the TissueFAXs microscope using 20X objective. Images were processed using Tissuequest software, selecting the cortex for automated analyses.

Luminescent conjugated oligothiophene (LCO) staining

For the Luminescent conjugated oligothiophenes (LCO) stainings, two different LCO variants, qFTAA (quadro-formyl thiophene acetic acid) and hFTAA (hepta-formyl thiophene acetic acid) were used. Blind-coded 30 μm sections were double-stained with qFTAA and hFTAA (2.4 μM qFTAA and 0.77 μM hFTAA in PBS) similar to a previous description (Nyström et al., 2013). Sections were incubated for 30 minutes in the dark at room temperature. Stainings were analyzed on the Zeiss LSM 510 META confocal microscope equipped with an argon 458 nm laser (Carl Zeiss MicroImaging GmbH, Jena, Germany). An 40x objective (oil-immersion, 1.3 NA, Zeiss) was used for spectral imaging of the A β deposits. Stacked images were acquired every 10 nm in the emission spectrum between 470 to 695 nm. Locations were selected randomly from the plaque containing regions of the temporal, frontal and occipital cortex. Images were analyzed using Fiji (Schindelin et al., 2012, 2015) and standard computer algorithms to provide a reproducible, unbiased detection of the plaques. First, the stacks of images across the different wavelengths of the spectrum were combined into one image using the Z-projection sum. A threshold was applied to the resulting image using the “Triangle dark” algorithm to automatically identify and delineate the plaques. Partial plaques on the edge of the images and particles smaller than 25 μm^2 were excluded. These settings allowed us to detect over 98 % of all the plaques in the images. The missed plaques were either too small or too low in intensity to be

accurately distinguished from the background. Incorrectly identified particles due to (lipofuscin) auto fluorescence were readily identified based on their wavelength intensity profile and visual inspection and were also excluded from the analysis. We identified between 17-25 plaques in each animal for the spectral intensity measurements. The ratio of the intensity of emitted light at the blue-shifted portion (502 nm) and red-shifted peak (588 nm) was used as a parameter for spectral distinction of different A β deposits. These peaks of the spectra were selected to maximize the spectral distinction.

Large-scale STEM (nanotomy)

The scanning transmission electron microscopy (STEM) experiments were adapted from previously described experiments (Kuipers et al., 2015). Briefly, paraffin embedded cortical sections of AM and AM;*Serf2*^{br/-} were deparaffinized and postfixes with 1 % osmium tetroxide/1.5 % potassium ferrocyanide in 0.1 M sodium cacodylate, dehydrated through ethanol and embedded in EPON (Serva) using a tissue processor (Leica EM TP 709202). Ultrathin sections (80 nm) were cut using the Leica uc7 ultramicrotome and collected on formvar coated copper grids (electron microscopy sciences, Hatfield, Pennsylvania). A large area scan using Scanning Transmission Detection was made using a Zeiss supra55 SEM with Atlas. STEM detection with a four quadrant STEM detector was used in inverted darkfield mode, at 28 kV with 30 μ m aperture at 3.5 mm working distance. All images were recorded at the same scan speed (cycle time 1.5 minute at 3072 $\times$ 2304 pixels). Contrast and brightness were set based on a live histogram. High resolution large-scale STEM images at 2.5 nm pixel size were generated with the external scan generator ATLAS (Fibics, Canada), individual tiles were stitched in VE viewer (Fibics, Canada), exported as a html-file and uploaded to the website www.nanotomy.org.

Cell culture

Mouse embryonic fibroblasts (MEFs) were isolated from *Serf2*^{+/+}, *Serf2*^{+/-} and *Serf2*^{-/-} E13.5 embryos. MEFs were cultured in T75 culture flasks (Greiner Bio-One, 658175), high-glucose Dulbecco's modified Eagle's medium (Gibco), supplemented with 10% fetal bovine serum (Sigma 12133C), 1 %

penicillin/streptomycin (Gibco), non-essential amino acids (Gibco) and β -mercaptoethanol at 37°C, 5 % CO₂ and 3 % O₂. E13.5 embryos. Wild-type HEK293T and two independent clonal lines of CRISPR *Serf2* KO mutant HEK 293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco; high glucose, pyruvate, 41966052), supplemented with 10 % Bovine Cow Serum (BCS; Sigma 12133C) and 1 % Penicillin/Streptomycin (Gibco; 10 000 U/mL, 15140122), at 37 °C, 5 % CO₂. For passaging of cells, 0.05 % Trypsin-EDTA (1X), Phenol Red (Invitrogen; 25300-054) was used. Regular mycoplasma tests were performed.

Cell proliferation assay

For the proliferation assay, 200 000 cells of each cell line were plated in triplicate in a standard 12-well plate and incubated inside the IncuCyte Zoom Live-Cell Imaging System (Essen Bioscience) for over 100 hours. The Incucyte system captured phase contrast images with a 10X magnification every 2 hours at nine distinct locations in each well to determine average confluency as a measure of cell growth. The quantification was performed using the IncuCyte Zoom software. The growth experiment was repeated three times. The confluency data of each experiment was normalized by min-max scaling and the average of the three experiments was plotted (solid line) with the standard deviation (dashed lines).

Statistical analysis

Unless specified otherwise, statistical analysis was performed using Graphpad v7.02. The exact statistical test used for each comparison is specified in the main body of the text, together with the resulting p-values. In the case of multiple comparisons, a post-hoc analysis with Bonferroni correction was performed. Any corrected p-values derived from this post-hoc analysis are indicated in the text as p_{bon} .

Data availability

RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-10083. (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-10083>)

Nanotomy datasets are open access available via the repository website www.nanotomy.org/PW/temp02/EllenNollen.

[to be deleted] Upon acceptance of this work the data will be open access available, without password. Pending acceptance, the website can only be accessed by collaborators and reviewers

Acknowledgments

All LCOs were kindly provided by K. Peter R. Nilsson, Linköping University, Sweden. Part of the work has been performed in the UMCG Microscopy and Imaging Center (UMIC), sponsored by ZonMW grant 91111.006 and NWO 40-00506-98-9021. We thank Ben Giepmans for advise on EM studies. This project was funded by a Meervoud Grant from NWO (836.09.001) (to E.A.A.N.), a European Research Council (ERC) starting grant (281622 PDControl) (to E.A.A.N.), the Alumni chapter Gooische Groningers facilitated by the Ubbo Emmius Fonds (to E.A.A.N), an Aspasia fellowship from NWO (015.014.005) (to E.A.A.N.).

Author Contributions

E.S., O.S., L.J. and E.A.A. conceptualized the project. E.S., L.J., O.S. and W.H. performed initial sample collection, sample processing and validation experiments verifying the Serf2 KO models and controls. M.K., L.H., S.A.Y. and A.d.B. provided the embryonic morphological and histological assessment. N.B. and M.J. provided the LCO staining and confocal imaging. A.H.G.W. performed the large-scale STEM imaging. B.B. and F.F. provided assistance in the isolation and RNA seq analysis of the MEFs. A.T. performed western blotting and ELISA measurements for APP and A β content.

616 B.v.d.S. and J.v.D. generated the initial Serf2KO animals. L.J. performed the data analysis and wrote
617 the manuscript in collaboration with E.S. and E.A.A.

618

619 **Conflict of Interests**

620 The authors declare that they have no conflict of interest.

References

1. Glenner, G. G. & Wong, C. W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem. Biophys. Res. Commun.* (1984). doi:10.1016/S0006-291X(84)80190-4
2. Masters, C. L. *et al.* Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. U. S. A.* **82**, 4245–4249 (1985).
3. Grundke-Iqbal, I. *et al.* Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J. Biol. Chem.* **261**, 6084–6089 (1986).
4. Grundke-Iqbal, I. *et al.* Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc. Natl. Acad. Sci. U. S. A.* **83**, 4913–4917 (1986).
5. Langley, C. H. & Charlesworth, B. *Nature* © Macmillan Publishers Ltd 1997 *expansion of xenotransplantation.* (1997).
6. Scherzinger, E. *et al.* Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology (huntingtinglutamine repeataggregation). *Medical Sciences Communicated by Max F. Perutz, Medical Research Council* **96**, 4604–4609 (1999).
7. Goate, A. *et al.* Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* **349**, 704–706 (1991).
8. Chartier-Harlin, M.-C. *et al.* Early-onset Alzheimer's disease caused by mutations at codon 717 of the β -amyloid precursor protein gene. *Nature* **353**, 844–846 (1991).
9. Citron, M. *et al.* Mutation of the β -amyloid precursor protein in familial Alzheimer's disease

- 643 increases β -protein production. *Nature* (1992). doi:10.1038/360672a0
- 644 10. Eckman, C. B. *et al.* A new pathogenic mutation in the APP gene (I716V) increases the relative
645 proportion of A beta 42(43). *Hum. Mol. Genet.* **6**, 2087–9 (1997).
- 646 11. Murrell, J. R., Hake, A. M., Quaid, K. A., Farlow, M. R. & Ghetti, B. Early-Onset Alzheimer
647 Disease Caused by a New Mutation (V717L) in the Amyloid Precursor Protein Gene. *Arch.*
648 *Neurol.* **57**, 885 (2000).
- 649 12. Kumar-Singh, S. *et al.* Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase
650 site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease.
651 *Hum. Mol. Genet.* **9**, 2589–98 (2000).
- 652 13. Cruts, M. *et al.* Novel APP mutation V715A associated with presenile Alzheimer's disease in a
653 German family. *J Neurol* **250**, 1374–1375 (2003).
- 654 14. Kumar-Singh, S. *et al.* Mean age-of-onset of familial Alzheimer disease caused by presenilin
655 mutations correlates with both increased A β 42 and decreased A β 40. *Hum. Mutat.* (2006).
656 doi:10.1002/humu.20336
- 657 15. Tomiyama, T. *et al.* A new amyloid β variant favoring oligomerization in Alzheimer's-type
658 dementia. *Ann. Neurol.* **63**, 377–387 (2008).
- 659 16. Schellenberg, G. *et al.* Genetic linkage evidence for a familial Alzheimer's disease locus on
660 chromosome 14. *Science* (80-.). **258**, 668–671 (1992).
- 661 17. Sherrington, R. *et al.* Cloning of a gene bearing missense mutations in early-onset familial
662 Alzheimer's disease. *Nature* **375**, 754–760 (1995).
- 663 18. Borchelt, D. R. *et al.* Familial Alzheimer's disease-linked presenilin I variants elevate a β 1-
664 42/1-40 ratio in vitro and in vivo. *Neuron* (1996). doi:10.1016/S0896-6273(00)80230-5

- 665 19. Lemere, C. A. *et al.* The E280A presenilin 1 Alzheimer mutation produces increased A beta 42
666 deposition and severe cerebellar pathology. *Nat. Med.* **2**, 1146–50 (1996).
- 667 20. Guerreiro, R. J. *et al.* Genetic screening of Alzheimer’s disease genes in Iberian and African
668 samples yields novel mutations in presenilins and APP. *Neurobiol. Aging* **31**, 725–731 (2010).
- 669 21. Rogaev, E. I. *et al.* Familial Alzheimer’s disease in kindreds with missense mutations in a gene
670 on chromosome 1 related to the Alzheimer’s disease type 3 gene. *Nature* **376**, 775–778 (1995).
- 671 22. Citron, M. *et al.* Mutant presenilins of Alzheimer’s disease increase production of 42-residue
672 amyloid beta-protein in both transfected cells and transgenic mice. *Nat. Med.* **3**, 67–72 (1997).
- 673 23. Müller, U., Winter, P., Bolender, C. & Nolte, D. Previously Unrecognized Missense Mutation
674 E126K of PSEN2 Segregates with Early Onset Alzheimer’s Disease in a Family. *J. Alzheimer’s*
675 *Dis.* **42**, 109–113 (2014).
- 676 24. Haass, C. *et al.* The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase
677 cleavage within the secretory pathway. *Nat. Med.* **1**, 1291–6 (1995).
- 678 25. Suzuki, N. *et al.* An increased percentage of long amyloid β protein secreted by familial
679 amyloid β protein precursor (β APP717) mutants. *Science* (80-.). (1994).
680 doi:10.1126/science.8191290
- 681 26. Duff, K. *et al.* Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1.
682 *Nature* (1996). doi:10.1038/383710a0
- 683 27. Murayama, O. *et al.* Enhancement of amyloid β 42 secretion by 28 different presenilin 1
684 mutations of familial Alzheimer’s disease. *Neurosci. Lett.* **265**, 61–63 (1999).
- 685 28. Nilsberth, C. *et al.* The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by
686 enhanced A β protofibril formation. *Nat. Neurosci.* **4**, 887–893 (2001).

29. Miravalle, L. *et al.* Substitutions at Codon 22 of Alzheimer's A Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells*. (2000). doi:10.1074/jbc.M003154200
30. Ni, C.-L., Shi, H.-P., Yu, H.-M., Chang, Y.-C. & Chen, Y.-R. Folding stability of amyloid- β 40 monomer is an important determinant of the nucleation kinetics in fibrillization. *FASEB J.* **25**, 1390–1401 (2011).
31. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α -synuclein linked to early-onset Parkinson disease. *Nat. Med.* (1998). doi:10.1038/3311
32. Narhi, L. *et al.* Both Familial Parkinson's Disease Mutations Accelerate α -Synuclein Aggregation. *J. Biol. Chem.* **274**, 9843–9846 (1999).
33. Conway, K. A. *et al.* Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. *Proc. Natl. Acad. Sci. U. S. A.* (2000). doi:10.1073/pnas.97.2.571
34. Ghosh, D. *et al.* The Parkinson's Disease-Associated H50Q Mutation Accelerates α -Synuclein Aggregation *in Vitro*. *Biochemistry* **52**, 6925–6927 (2013).
35. Ghosh, D. *et al.* The Newly Discovered Parkinson's Disease Associated Finnish Mutation (A53E) Attenuates α -Synuclein Aggregation and Membrane Binding. *Biochemistry* **53**, 6419–6421 (2014).
36. Choi, W. *et al.* Mutation E46K increases phospholipid binding and assembly into filaments of human α -synuclein. *FEBS Lett.* **576**, 363–368 (2004).
37. Cooper, J. K. *et al.* Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. *Hum. Mol. Genet.* (1998).

710 doi:10.1093/hmg/7.5.783

- 711 38. Nekooki-Machida, Y. *et al.* Distinct conformations of in vitro and in vivo amyloids of
712 huntingtin-exon1 show different cytotoxicity. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 9679–84
713 (2009).
- 714 39. Sun, C.-S. *et al.* Conformational switch of polyglutamine-expanded huntingtin into benign
715 aggregates leads to neuroprotective effect. *Sci. Rep.* **5**, 14992 (2015).
- 716 40. Cohen, M. L. *et al.* Rapidly progressive Alzheimer's disease features distinct structures of
717 amyloid- β . *Brain* **138**, 1009–1022 (2015).
- 718 41. Qiang, W., Yau, W.-M., Lu, J.-X., Collinge, J. & Tycko, R. Structural variation in amyloid- β
719 fibrils from Alzheimer's disease clinical subtypes. *Nature* **541**, 217–221 (2017).
- 720 42. Bousset, L. *et al.* Structural and functional characterization of two alpha-synuclein strains. *Nat.*
721 *Commun.* **4**, 2575 (2013).
- 722 43. Heise, H. *et al.* Solid-State NMR Reveals Structural Differences between Fibrils of Wild-Type
723 and Disease-Related A53T Mutant α -Synuclein. *J. Mol. Biol.* **380**, 444–450 (2008).
- 724 44. Li, B. *et al.* Cryo-EM of full-length α -synuclein reveals fibril polymorphs with a common
725 structural kernel. *Nat. Commun.* **9**, 3609 (2018).
- 726 45. Guerrero-Ferreira, R. *et al.* Two new polymorphic structures of alpha-synuclein solved by
727 cryo-electron microscopy. *bioRxiv* 654582 (2019). doi:10.1101/654582
- 728 46. Gath, J. *et al.* Unlike Twins: An NMR Comparison of Two α -Synuclein Polymorphs Featuring
729 Different Toxicity. *PLoS One* **9**, e90659 (2014).
- 730 47. Cohen, E. *et al.* Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice. *Cell*

731 **139**, 1157–1169 (2009).

732 48. Lu, J. X. *et al.* Molecular structure of β -amyloid fibrils in alzheimer's disease brain tissue. *Cell*
733 (2013). doi:10.1016/j.cell.2013.08.035

734 49. Rasmussen, J. *et al.* Amyloid polymorphisms constitute distinct clouds of conformational
735 variants in different etiological subtypes of Alzheimer's disease. *Proc. Natl. Acad. Sci.* **114**,
736 13018–13023 (2017).

737 50. van Ham, T. J. *et al.* Identification of MOAG-4/SERF as a regulator of age-related
738 proteotoxicity. *Cell* **142**, 601–612 (2010).

739 51. Falsone, S. F. *et al.* SERF Protein Is a Direct Modifier of Amyloid Fiber Assembly. *Cell Rep.*
740 **2**, 358–371 (2012).

741 52. Yoshimura, Y. *et al.* MOAG-4 promotes the aggregation of α -synuclein by competing with
742 self-protective electrostatic interactions. *J. Biol. Chem.* **292**, 8269–8278 (2017).

743 53. Merle, D. A. *et al.* Increased Aggregation Tendency of Alpha-Synuclein in a Fully Disordered
744 Protein Complex. *J. Mol. Biol.* **431**, 2581–2598 (2019).

745 54. Kaufman, M. H. *The Atlas of Mouse Development*. (Elsevier Science, 1992).

746 55. Kaufman, M. H. & Bard, J. B. L. *The Anatomical Basis of Mouse Development*. (Elsevier
747 Science, 1999).

748 56. Ward, J. M., Elmore, S. A. & Foley, J. F. Pathology Methods for the Evaluation of Embryonic
749 and Perinatal Developmental Defects and Lethality in Genetically Engineered Mice. *Vet.*
750 *Pathol.* **49**, 71–84 (2012).

751 57. Ciemerych, M. A. & Sicinski, P. Cell cycle in mouse development. *Oncogene* (2005).

doi:10.1038/sj.onc.1208608

58. Takashima, Y. *et al.* Neuroepithelial Cells Supply an Initial Transient Wave of MSC Differentiation. *Cell* **129**, 1377–1388 (2007).
59. Pevny, L. H., Sockanathan, S., Placzek, M. & Lovell-Badge, R. A role for SOX1 in neural determination. *Development* (1998).
60. Wood, H. B. & Episkopou, V. Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages. *Mech. Dev.* (1999). doi:10.1016/S0925-4773(99)00116-1
61. Radde, R. *et al.* Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep.* **7**, 940–6 (2006).
62. Klingstedt, T. *et al.* Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. *Org. Biomol. Chem.* **9**, 8356–70 (2011).
63. Psonka-Antonczyk, K. M. *et al.* Nanoscale Structure and Spectroscopic Probing of Aβ1-40 Fibril Bundle Formation. *Front. Chem.* (2016). doi:10.3389/fchem.2016.00044
64. Nyström, S. *et al.* Evidence for Age-Dependent in Vivo Conformational Rearrangement within Aβ Amyloid Deposits. *ACS Chem. Biol.* **8**, 1128–1133 (2013).
65. Lord, A. *et al.* Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease. *Am. J. Pathol.* **178**, 2286–2298 (2011).
66. Meyer, N. H. *et al.* Structural fuzziness of the RNA-organizing protein SERF1a determines a toxic gain-of-interaction. *bioRxiv* 713511 (2019). doi:10.1101/713511
67. Murray, S. A. *et al.* Mouse Gestation Length Is Genetically Determined. *PLoS One* **5**, e12418

773 (2010).

774 68. Visintin, R. & Amon, A. The nucleolus: the magician's hat for cell cycle tricks. *Curr. Opin.*
775 *Cell Biol.* **12**, 372–377 (2000).

776 69. Leung, A. K. L. *et al.* Quantitative kinetic analysis of nucleolar breakdown and reassembly
777 during mitosis in live human cells. *J. Cell Biol.* **166**, 787–800 (2004).

778 70. Petkova, A. T. *et al.* Self-propagating, molecular-level polymorphism in Alzheimer's β -
779 amyloid fibrils. *Science* (80-.). (2005). doi:10.1126/science.1105850

780 71. Meinen, B. A., Gadkari, V. V., Stull, F., Ruotolo, B. T. & Bardwell, J. C. A. SERF engages in
781 a fuzzy complex that accelerates primary nucleation of amyloid proteins. *Proc. Natl. Acad. Sci.*
782 (2019). doi:10.1073/pnas.1913316116

783 72. Pras, A. *et al.* The cellular modifier MOAG-4/SERF drives amyloid formation through charge
784 complementation. *bioRxiv* 2020.12.09.417709 (2020). doi:10.1101/2020.12.09.417709

785 73. Grant, M. A. *et al.* *Familial Alzheimer's disease mutations alter the stability of the amyloid-*
786 *protein monomer folding nucleus.* **104**, (2007).

787 74. Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C. & Teplow, D. B. On the nucleation of
788 amyloid β -protein monomer folding. *Protein Sci.* **14**, 1581–1596 (2009).

789 75. Elkins, M. R. *et al.* Structural Polymorphism of Alzheimer's β -Amyloid Fibrils as Controlled
790 by an E22 Switch: A Solid-State NMR Study. (2016). doi:10.1021/jacs.6b03715

791 76. Ovchinnikova, O. Y., Finder, V. H., Vodopivec, I., Nitsch, R. M. & Glockshuber, R. The
792 Osaka FAD Mutation E22 Δ Leads to the Formation of a Previously Unknown Type of
793 Amyloid β Fibrils and Modulates A β Neurotoxicity. *J. Mol. Biol.* **408**, 780–791 (2011).

- 794 77. Van Nostrand, W. E., Melchor, J. P., Cho, H. S., Greenberg, S. M. & Rebeck, G. W.
795 Pathogenic effects of D23N Iowa mutant amyloid beta -protein. *J. Biol. Chem.* **276**, 32860–6
796 (2001).
- 797 78. Inayathullah, M. & Teplow, D. B. Structural dynamics of the ΔE22 (Osaka) familial
798 Alzheimer's disease-linked amyloid β-protein. *Amyloid* **18**, 98–107 (2011).
- 799 79. Bugiani, O. *et al.* Hereditary Cerebral Hemorrhage With Amyloidosis Associated With the
800 E693K Mutation of APP. *Arch. Neurol.* **67**, 987–995 (2010).
- 801 80. Grabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W. & Greenberg, S. M. Novel
802 amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral
803 amyloid angiopathy. *Ann. Neurol.* **49**, 697–705 (2001).
- 804 81. Philipson, O. *et al.* A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is
805 found in Arctic APP transgenic mice. *Neurobiol. Aging* **30**, 1393–1405 (2009).
- 806 82. Shimada, H. *et al.* Clinical course of patients with familial early-onset Alzheimer's disease
807 potentially lacking senile plaques bearing the E693Δ mutation in amyloid precursor protein.
808 *Dement. Geriatr. Cogn. Disord.* **32**, 45–54 (2011).
- 809 83. Tomiyama, T. *et al.* A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic
810 Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo. *J.*
811 *Neurosci.* **30**, 4845–4856 (2010).
- 812 84. Lord, A. *et al.* The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation
813 and senile plaque formation in transgenic mice. *Neurobiol. Aging* **27**, 67–77 (2006).
- 814 85. Kulic, L. *et al.* Early accumulation of intracellular fibrillar oligomers and late congophilic
815 amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation. *Transl. Psychiatry*
816 **2**, e183–e183 (2012).

86. Philipson, O. *et al.* The Arctic amyloid- β precursor protein (A β PP) mutation results in distinct plaques and accumulation of N- and C-truncated A β . *Neurobiol. Aging* **33**, 1010.e1-1010.e13 (2012).
87. Skarnes, W. C. *et al.* A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* **474**, 337–342 (2011).
88. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).
89. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **37**, 1–13 (2009).
90. Huang, Y. *et al.* Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models. *Sci. Transl. Med.* **7**, 309ra164 (2015).
91. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).

Figure legends

Figure 1. Full-body *Serf2*^{-/-} mice display a developmental delay and perinatal lethality. (A)

Schematic overview of the crossing scheme with full-body *Serf2*^{+/-} mice and the resulting genotypic composition of the offspring at embryonic and postnatal stage. (B) Absolute animal counts for the three genotypes in the offspring at various days of embryonic development (E13.5, E15.5 and E17.5), at birth (P0) and at time of weaning (P22). (C) Real time RT-PCR analyses of *Serf1* and *Serf2* RNA levels in E13.5 heads normalized to housekeeping gene beta-actin (n=4/group, mean±SD, One-way ANOVA for each gene, Bonferroni corrected post-hoc comparison between genotypes ***p<0.001). (D) Western blot of SERF2 and actin in *Serf2*^{+/+}, *Serf2*^{+/-}, *Serf2*^{-/-} embryos at E13.5 (black arrow indicates SERF2 band). (E) Length measurements of *Serf2*^{+/+}, *Serf2*^{+/-}, *Serf2*^{-/-} embryos at E15.5, E17.5 and P0 (black line = mean, Two-way ANOVA with factors age and genotype, Bonferroni corrected post-hoc comparison for *Serf2*^{+/-} and *Serf2*^{-/-} compared to *Serf2*^{+/+} *p<0.05; ***p<0.001). (F) Hematoxylin and eosin stained lung tissue from *Serf2*^{+/+} and *Serf2*^{-/-} pups at P0 (top: *Serf2*^{-/-}, bottom: *Serf2*^{+/+}, scale bar=500µm, rectangle =5x magnification in right picture). (G) Quantification of the saccular space in lung tissue from *Serf2*^{+/+} and *Serf2*^{-/-} pups at P0 (black line = mean, t-test **p<0.01). For all mouse data panels: *Serf2*^{+/+} = black, *Serf2*^{+/-} = dark grey, *Serf2*^{-/-} = light grey.

Figure 2. Crossing a conditional *Serf2* KO with an AM background does not affect the overall levels of APP and Aβ. (A) Schematic overview of the cross between brain-specific *Serf2* KO mice and the amyloid model resulting in four experimental groups: WT, *Serf2*^{br/-}, AM and AM;*Serf2*^{br/-}.

(B) Timeline for the Aβ pathology in the amyloid model and the selected time points for this study. (C) Real time RT-PCR analyses of *Serf2* RNA levels in the brain tissue of all experimental groups at 1 and 3 months of age normalized to housekeeping gene beta-actin (n=6/group, mean±SD, Two-way ANOVA with factors age and genotype, Bonferroni corrected post-hoc for individual groups compared to WT). (D) Western blot of SERF2 and actin in brain tissue of all experimental groups at 1 and 3 months of age. (E) Brain weight of all experimental groups at 1 and 3 months of age (black line = mean, Two-way ANOVA with factors age and genotype, Bonferroni corrected post-hoc for

individual groups compared to WT). **(F)** Brain weight of unfloxed control groups at 3 months of age (black line = mean, One-way ANOVA, Bonferroni corrected post-hoc for individual groups compared to WT). **(G)** Number of cortical nuclei per mm² in hematoxylin and eosin stained brain tissue of all experimental groups at 3 months of age. (n=3/group, mean±SD, Kruskal-Wallis p=0.5566). **(H)** Real time RT-PCR analyses of APP RNA levels in the brain tissue of AM and AM;*Serf2*^{br/-} mice at 1 and 3 months of age normalized to housekeeping gene beta-actin (n=6/group, mean±SD, t-test between genotypes at both ages not significant). **(I)** Western blot of APP and beta-actin in brain tissue of AM and AM;*Serf2*^{br/-} mice at 3 months of age versus 1-month-old non-AM controls. **(J)** Quantification of total APP protein levels in brains of AM and AM;*Serf2*^{br/-} mice at 1 and 3 months of age normalized to beta-actin levels. (black line = mean, t-test between genotypes at both ages not significant). **(K)** Aβ₄₀ and **(L)** Aβ₄₂ levels in brain lysate from AM and AM;*Serf2*^{br/-} mice at 1 and 3 months of age as determined by ELISA normalized to total protein content. (black line = mean, t-test between genotypes at both ages not significant). **(M)** Correlation plot depicting the relationship between Aβ₄₀ and Aβ₄₂ levels in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age (detailed statistics in Supplemental Table 3). In panels A-L: WT = black, *Serf2*^{br/-} = light grey, AM = dark grey and AM;*Serf2*^{br/-} = white; ***p<0.001; **p<0.01.

Figure 3. Brain-specific *Serf2* KO display increased Aβ deposition and amyloid. **(A)** Detailed light microscope images of the 6E10-stained cortical region marked on the sagittal section in Supplemental Figure 5 from 3-month-old AM and AM;*Serf2*^{br/-} mice (scale bar = 100μm). **(B)** Quantification of the Aβ deposits in the region of interest (ROI) of 6E10 immunostained sagittal brain sections from 1- and 3-month-old AM and AM;*Serf2*^{br/-} mice (black line = mean, One-way ANOVA between genotypes at both ages, Bonferroni corrected post-hoc between AM and AM;*Serf2*^{br/-} not significant). **(C)** Correlation plot depicting the relationship between Aβ₄₀ levels and 6E10 plaque density in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(D)** Correlation plot depicting the relationship between Aβ₄₂ levels and 6E10 plaque density in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(E)** Quantification of the Aβ deposits in the ROI of W0-2 immunostained sagittal brain sections from 1- and 3-month-old AM and AM;*Serf2*^{br/-} mice (black line = mean, One-way ANOVA

between genotypes at both ages, Bonferroni corrected post-hoc between AM and AM;*Serf2*^{br/-} not significant). **(F)** Correlation plot depicting the relationship between 6E10 deposits and W0-2 deposits in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(G)** Quantification of the plaque density in the ROI of Thioflavin-S stained sagittal brain sections from 1- and 3-month-old AM and AM;*Serf2*^{br/-} mice (black line = mean, One-way ANOVA between genotypes at both ages, Bonferroni corrected post-hoc between AM and AM;*Serf2*^{br/-} not significant). **(H)** Correlation plot depicting the relationship between A β ₄₀ levels and ThS plaque density in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(I)** Correlation plot depicting the relationship between A β ₄₂ levels and ThS plaque density in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(J)** Correlation plot depicting the relationship between 6E10 deposits and ThS plaques in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. In all panels ROI = cortical and hippocampal area; In panels B,E and G: WT = black, *Serf2*^{br/-} = light grey, AM = dark grey and AM;*Serf2*^{br/-} = white; for correlation plots: detailed statistics in Supplemental Table 3; ***p<0.001; **p<0.01; *p<0.05.

Figure 4. Brain-specific *Serf2* KO alters the structural composition of amyloid plaques. (A)

Graph showing the theoretical LCO dye emission spectra for qFTAA, which binds mature A β fibrils (blue), and hFTAA, which binds both mature fibrils and prefibrillar A β species (red). **(B)** Frequency distribution of the ratio in fluorescence intensity at 502 nm and 588 nm for all amyloid plaques identified by confocal microscopy in AM (blue) and AM;*Serf2*^{br/-} (red) mice at 3 months of age. Three peak frequency categories were identified: low IR(red), medium IR (green) and high IR (blue) (n=6 mice/genotype). **(C)** Dot plot representing the intensity ratio of all amyloid plaques identified by confocal microscopy for AM and AM;*Serf2*^{br/-} mice at 3 months of age (colors represent the IR categories defined in panel B, black circles correspond to the plaques depicted in panel E, black line = mean, t-test ***p<0.001) (n=6 mice/genotype). **(D)** Correlation plot depicting the relationship between 6E10 plaque density in the ROI and the LCO average intensity ratio in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age (ROI = cortical and hippocampal area, detailed statistics in Supplemental Table 3). **(E)** Spectral confocal microscopy images of amyloid plaques in AM and AM;*Serf2*^{br/-} mice at 3 months of age of double stained with qFTAA and hFTAA (top= fluorescence

912 at 502 nm, middle= fluorescence at 588 nm, bottom=merged image of 502 nm and 588 nm
 913 fluorescence, scale bar = 5 μ m). **(F)** Scanning transmission electron microscopy pictures of amyloid
 914 plaques in the cortex of AM and AM;*Serf2*^{br/-} mice at 3 months of age (top scale bar 5 μ m, rectangle =
 915 zoomed region in bottom picture, bottom scale bar = 1 μ m). High-resolution EM images are available
 916 via <http://www.nanotomy.org>.

Figure 1

Figure 2

Figure 3

Figure 4

Supplemental figure legends

Supplemental Figure 1. Additional full-body *Serf2*^{-/-} mice validation and phenotype confirmation. (A) Targeting strategy used to delete exon 2 of *Serf2* by using the ‘knockout-first’-allele (adjusted from Skarnes et al. 2011). Top panel: exon/intron structure of *Serf2* including the positions of the LacZ and Neo cassettes, as well as loxP sites. Bottom panel: the *Serf2* allele after recombination events as a result of crosses with *Hprt-Cre* mice. (B) Western blot analysis of liver, heart and brain tissue of a *Serf2*^{+/+}, *Serf2*^{+/-} and *Serf2*^{-/-} adult mice to detect Serf2 and actin. (C) Real time RT-PCR analyses of *Serf2* in different organs of adult mice with the following genotypes *Serf2*^{+/+} (n=3), *Serf2*^{+/-} (n=8) and *Serf2*^{-/-} (n=1). *Serf2* levels were normalized to the housekeeping gene 18S (mean ± SEM). (D) Lateral view of a *Serf2*^{-/-} and *Serf2*^{+/-} embryo and placenta at embryonic day 15.5 and 17.5. (E) Weight measurements of *Serf2*^{+/+}, *Serf2*^{+/-}, *Serf2*^{-/-} embryos at E17.5 and P0 (black line = mean, Two-way ANOVA with factors age and genotype, Bonferroni corrected post-hoc comparison for *Serf2*^{+/-} and *Serf2*^{-/-} compared to *Serf2*^{-/-} *p<0.05; ***p<0.001). (F) Hematoxylin and Eosin staining on *Serf2*^{-/-} and *Serf2*^{+/+} lung and kidney tissue at E17.5 (10 times magnification). For all panels: *Serf2*^{+/+} = black, *Serf2*^{+/-} = dark grey, *Serf2*^{-/-} = light grey.

Supplemental Figure 2. Cell culture data of *Serf2* KO and control HEK cells and RNA sequencing analysis of mouse embryonic fibroblasts (MEFs) isolated from full-body *Serf2*^{-/-} and control mice. (A) Growth curve of two CRISPR-induced *Serf2*^{-/-} clones of HEK293T versus wild-type HEK293T. (Three replicates measured, full line=replicate average, dashed lines=standard deviation on average) (B) Network showing the interconnectivity of enriched GO-terms in RNA sequencing data from *Serf2*^{-/-} and control MEFs. Circle size indicates amount of differentially expressed genes found in each GO-category. Edges were drawn when the minor category shared more than 25 % of its found genes with the major category. Edge color indicates the major category in the relationship. Edge thickness indicates the percentage of found genes shared by the minor category. (C) Bar chart indicating the fold change for each GO-term as determined by DAVID. Brackets indicate the three main GO-term clusters defined based on the network in (B).

Supplemental Figure 3. Additional validation of the brain-specific knock-out of *Serf2*. (A)

Modified targeting strategy used to delete the exon 2 of *Serf2* specifically in the central nervous system. **(B)** Real time RT-PCR analyses of *Serf2* RNA expression in different organs *Serf2*^{+/+} and *Serf2*^{br/-} female mice at 1 month and 3 months of age. *Serf2* expression was normalized to housekeeping gene beta-actin (all groups n=6, mean ± SEM). **(C)** Western blot analysis and quantification of *Serf2* and beta-actin in brain lysates of WT and *Serf2*^{br/-} female mice at 1 month (both groups n=6, mean ± SEM, t-test **p<0.01). **(D)** Brain weight of unfloxed WT and CRE^{br} mice at 1 and 3 months of age (black line = mean, Two-way ANOVA with factors age and genotype, Bonferroni corrected post-hoc for CRE^{br} compared to WT *p_{bon}<0.05). **(E)** Evolution of brain weight in WT and *Serf2*^{br/-} female mice between 1 and 11 months of age (black line = mean).

Supplemental Figure 4. Overview of distribution and general morphological parameters of

6E10-stained Aβ deposits in AM and AM;*Serf2*^{br/-} mice at 3 months of age. (A) Light microscope

images of the 6E10 immunostained sagittal section of 3-month-old AM and AM;*Serf2*^{br/-} female mice (scale bar = 1mm, black rectangle = magnified region in main Figure 3). **(B)** Boxplots showing the distribution of the surface area of the individual plaques measured in AM and AM;*Serf2*^{br/-} mice at 3 months of age. **(C)** Boxplots showing the distribution of the circularity of the individual plaques measured in AM and AM;*Serf2*^{br/-} mice at 3 months of age. **(D)** Boxplots showing the distribution of the solidity of the individual plaques measured in AM and AM;*Serf2*^{br/-} mice at 3 months of age. For all boxplots: black line = median, box = 25th-75th percentile, whiskers = 1.5 x interquartile range (IQR), circles = outlier value > 1.5x IQR, asterisks = extreme outlier value > 3x IQR.

Supplemental Figure 5. Overview of distribution and detailed W0-2-stained Aβ deposits in AM

and AM;*Serf2*^{br/-} mice at 3 months of age. Light microscope images of the W0-2 immunostained

sagittal section of 3-month-old AM and AM;*Serf2*^{br/-} female mice (scale bar = 1mm, black rectangle = magnified in insert on the right, insert scale bar = 100μm).

Supplemental Figure 6. Correlation plots illustrating the relationship of different stains in

individual mice. (A) Correlation plot depicting the relationship between the density of 6E10 deposits

969 and Iba1-positive spots in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(B)**
 970 Correlation plot depicting the relationship between W0-2 plaque density and the LCO average
 971 intensity ratio in AM (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. **(C)** Correlation plot
 972 depicting the relationship between ThS plaque density and the LCO average intensity ratio in AM
 973 (black) and AM;*Serf2*^{br/-} (grey) mice at 3 months of age. For all plots: detailed statistics in
 974 Supplemental Table 3; *p < 0.05.

975 **Supplemental Figure 7. Overview and detailed view of Aβ staining pattern after W0-2 and 6E10**
 976 **staining in AM and AM;*Serf2*^{br/-} mice at 1 month of age. (A)** Light microscope images of the W0-2
 977 immunostained sagittal section of 1-month-old AM and AM;*Serf2*^{br/-} female mice. **(B)** Light
 978 microscope images of the 6E10 immunostained sagittal section of 1-month-old AM and AM;*Serf2*^{br/-}
 979 female mice. All pictures: main scale bar = 1mm, black rectangle = magnified in insert on the right,
 980 insert scale bar = 100μm.